KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Net Cash Flow (2016 - 2025)

Pfizer (PFE) has disclosed Net Cash Flow for 17 consecutive years, with -$202.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 1162.5% to -$202.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $49.0 million, a 102.81% increase, with the full-year FY2025 number at $49.0 million, up 102.81% from a year prior.
  • Net Cash Flow was -$202.0 million for Q4 2025 at Pfizer, up from -$304.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $1.8 billion in Q2 2023 to a low of -$2.1 billion in Q1 2024.
  • A 5-year average of $57.1 million and a median of $97.0 million in 2024 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: skyrocketed 3633.33% in 2022, then tumbled 1547.62% in 2025.
  • Pfizer's Net Cash Flow stood at $241.0 million in 2021, then tumbled by 310.37% to -$507.0 million in 2022, then soared by 38.07% to -$314.0 million in 2023, then soared by 94.9% to -$16.0 million in 2024, then plummeted by 1162.5% to -$202.0 million in 2025.
  • Per Business Quant, the three most recent readings for PFE's Net Cash Flow are -$202.0 million (Q4 2025), -$304.0 million (Q3 2025), and $173.0 million (Q2 2025).